# Watch: Sanofi to buy maker of hemophilia drug Bioverativ for $11.5b

Published 2018-01-22 · Updated 2026-03-12 · Healthcare on MarketScale
Canonical: https://www.marketscale.com/industries/healthcare/watch-sanofi-buy-maker-hemophilia-drug-bioverativ-11-5b

> Sanofi announced the purchase of Bioverativ, French maker of a drug treating hemophilia. The deal will close within three months and values Bioverativ at a 63% premium of their market price. Sanofi lost out on major deals in 2016 and hopes adding Bioverativ will boost its rare-disease business. Market competition is on the rise as…

Sanofi announced the purchase of Bioverativ, French maker of a drug treating hemophilia. The deal will close within three months and values Bioverativ at a 63% premium of their market price. Sanofi lost out on major deals in 2016 and hopes adding Bioverativ will boost its rare-disease business. Market competition is on the rise as new heavyweight firms gain traction.

---
Source: MarketScale, https://www.marketscale.com/industries/healthcare/watch-sanofi-buy-maker-hemophilia-drug-bioverativ-11-5b. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt